ascopubs.org

EGFR mutations (muts), IHC and FISH status, and chromosome 7 gene copy number combined with pAkt expression as potential predictors of survival in non-small cell lung cancer ...

This is an ASCO Meeting Abstract from the 2006 ASCO Annual Meeting. This abstract does not include a full text component.
WebMD

EGFR Mutations in NSCLC: What Does It Mean?

Epidermal growth factor receptor (EGFR) is a protein on the surface of your cells that helps them grow. When the gene that codes for EGFR has a mutation, it affects the way this protein works, causing ...
Business Wire

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World ...

Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib ...
Hosted on MSN

Targeted Drug Tagrisso Leads To More Tumor Shrinkage For Lung Cancer Patients With EGFR Mutation: Unpacking The New Data

Patients with a certain type of lung cancer — stage II to IIIB non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation — saw better results when treated with the ...
Cure Today

What Patients With Lung Cancer Need to Know About EGFR PACC Mutations

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
Morningstar

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, ...
EurekAlert!

Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report

Hematoxylin and eosin staining revealed poorly differentiated carcinoma with round cells and rhabdoid morphology (A, 100×). Positive expression of CK5/6 (B, 100×) and CK7 (C, 100×). Suggestive SMARCA4 ...
Monthly Prescribing Reference

Tagrisso Approved for First-Line Tx of EGFR Mutation Positive Advanced NSCLC

Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
Monthly Prescribing Reference

Osimertinib Plus Chemotherapy Under Review for EGFR Mutation Positive NSCLC

Credit: Getty Images. Osimertinib, a kinase inhibitor, is currently marketed under the brand name Tagrisso. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New ...
Hosted on MSN

ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations

NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients ...
Nasdaq

HUTCHMED Reports Positive Results from SACHI Phase III Study of Savolitinib and Osimertinib in EGFR Mutation-Positive NSCLC

HUTCHMED announced significant findings from the SACHI Phase III study, which investigated the combination of savolitinib and osimertinib in treating patients with locally advanced or metastatic EGFR ...